Akums Drugs

68
Hold
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE09XN01023
  • NSEID: AKUMS
  • BSEID: 544222
INR
609.65
-4 (-0.65%)
BSENSE

Jun 25, 12:24 PM

BSE+NSE Vol: 85.46 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Operating Income
4,359.00
4,118.00
4,178.00
3,654.00
3,671.00
2,722.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
4,359.00
4,118.00
4,178.00
3,654.00
3,671.00
2,722.00
Expenditure (Ex Depriciation)
Stock Adjustments
13.00
-1.00
12.00
24.00
-87.00
-30.00
Raw Materials Consumed
2,499.00
2,435.00
2,537.00
2,249.00
2,432.00
1,721.00
Power & Fuel Cost
184.00
164.00
160.00
147.00
110.00
76.00
Employee Cost
753.00
715.00
646.00
590.00
507.00
420.00
Operating Expenses
110.00
98.00
102.00
108.00
104.00
81.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
53.00
55.00
55.00
54.00
51.00
23.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
96.00
87.00
434.00
76.00
568.00
139.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
3,836.00
3,657.00
4,055.00
3,360.00
3,763.00
2,485.00
Operating Profit (PBDIT) excl Other Income
522.00
460.00
122.00
293.00
-91.00
237.00
Other Income
128.00
55.00
34.00
90.00
22.00
21.00
Operating Profit (PBDIT)
650.00
516.00
157.00
384.00
-69.00
258.00
Interest
94.00
34.00
50.00
46.00
16.00
6.00
Profit before Depriciation and Tax
556.00
482.00
106.00
337.00
-85.00
251.00
Depreciation
154.00
153.00
125.00
112.00
94.00
69.00
Profit Before Taxation & Exceptional Items
402.00
328.00
-19.00
225.00
-180.00
181.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
382.00
345.00
-45.00
150.00
-193.00
172.00
Provision for Tax
125.00
1.00
-46.00
52.00
57.00
48.00
Profit After Tax
256.00
343.00
0.00
98.00
-251.00
123.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
1,829.00
630.00
638.00
557.00
832.00
770.00
Profit Available for appropriations
2,084.00
969.00
634.00
652.00
579.00
894.00
Appropriations
2,084.00
969.00
634.00
652.00
579.00
894.00
Equity Dividend (%)
150.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Earnings Per Share
16.67
22.60
-0.28
6.63
-17.65
949.08
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is 5.85% vs -1.44% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is 13.33% vs 274.53% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is 171.89% vs -31.64% in Mar 2025

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2026 is -25.42% vs 43,416.08% in Mar 2025

Compare Profit and Loss Results of Akums Drugs
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
4,359.00
4,565.00
-206.00
-4.51%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
4,359.00
4,565.00
-206.00
-4.51%
Expenditure (Ex Depriciation)
Stock Adjustments
13.00
-184.00
197.00
107.07%
Raw Materials Consumed
2,499.00
2,163.00
336.00
15.53%
Power & Fuel Cost
184.00
58.00
126.00
217.24%
Employee Cost
753.00
862.00
-109.00
-12.65%
Operating Expenses
110.00
302.00
-192.00
-63.58%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
53.00
298.00
-245.00
-82.21%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
96.00
41.00
55.00
134.15%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
3,836.00
3,762.00
74.00
1.97%
Operating Profit (PBDIT) excl Other Income
522.00
802.00
-280.00
-34.91%
Other Income
128.00
58.00
70.00
120.69%
Operating Profit (PBDIT)
650.00
861.00
-211.00
-24.51%
Interest
94.00
248.00
-154.00
-62.10%
Profit before Depriciation and Tax
556.00
612.00
-56.00
-9.15%
Depreciation
154.00
192.00
-38.00
-19.79%
Profit Before Taxation & Exceptional Items
402.00
420.00
-18.00
-4.29%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
382.00
486.00
-104.00
-21.40%
Provision for Tax
125.00
77.00
48.00
62.34%
Profit After Tax
256.00
407.00
-151.00
-37.10%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
1,829.00
-284.00
2,113.00
744.01%
Profit Available for appropriations
2,084.00
120.00
1,964.00
1,636.67%
Appropriations
2,084.00
120.00
1,964.00
1,636.67%
Equity Dividend (%)
150%
40%
110.00
Earnings Per Share
16.67
390.55
-373.88
-95.73%
Profit And Loss - Net Sales
Net Sales 4,359.02 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 5.85% vs -1.44% in Mar 2025

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 522.02 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 13.33% vs 274.53% in Mar 2025

Profit And Loss - Interest
Interest 94.07 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is 171.89% vs -31.64% in Mar 2025

Profit And Loss - Profit After Tax
Profit After Tax 256.40 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -25.42% vs 43,416.08% in Mar 2025